PMID- 31228094
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20200724
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 14
IP  - 4
DP  - 2019 Aug
TI  - Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.
PG  - 228-238
LID - 10.1007/s11899-019-00519-7 [doi]
AB  - PURPOSE OF REVIEW: Diffuse large B cell lymphoma (DLBCL) is a curable and common 
      malignancy in elderly population. Elderly patients, especially those 80 and 
      older, have poor outcomes compared with those < 60. This may be due to the 
      disease biology, comorbidities, and/or functional limitations. RECENT FINDINGS: 
      Prospective data, and especially randomized data, are limited. The FIL tool 
      objectively categorizes patients as fit, unfit, or frail. Fit and unfit patients 
      can benefit from chemoimmunotherapy with curative intent. Evidence guiding 
      treatment of frail patients is limited, but it appears that frail patients have 
      similar survival regardless of treatment with curative or palliative intent. For 
      fit and unfit patients, treatment options include rituximab with dose-attenuated 
      CHOP or regimens with adriamycin alternatives if there is concern for 
      cardiovascular adverse effects (AEs). Frail patients are extremely sensitive to 
      toxicity from therapies. Frail patients and those 80 and older could greatly 
      benefit from trials incorporating novel agents.
FAU - Khan, Yasir
AU  - Khan Y
AD  - Department of Medicine, Division of Hematology/Oncology, University of 
      California, Irvine, Irvine, CA, USA.
FAU - Brem, Elizabeth A
AU  - Brem EA
AD  - Department of Medicine, Division of Hematology/Oncology, University of 
      California, Irvine, Irvine, CA, USA. ebrem@uci.edu.
AD  - Departmentof Medicine, Division of Hematology/Oncology, University of California, 
      Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA. ebrem@uci.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
RN  - 0 (R-CHOP protocol)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Clinical Decision-Making
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/adverse effects/therapeutic use
MH  - Disease Management
MH  - Doxorubicin/adverse effects/therapeutic use
MH  - Geriatric Assessment
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/diagnosis/etiology/*therapy
MH  - Palliative Care
MH  - Prednisone/adverse effects/therapeutic use
MH  - Rituximab/adverse effects/therapeutic use
MH  - Treatment Outcome
MH  - Vincristine/adverse effects/therapeutic use
OTO - NOTNLM
OT  - DLBCL
OT  - Elderly
OT  - Frailty
OT  - Lymphoma
EDAT- 2019/06/23 06:00
MHDA- 2020/07/25 06:00
CRDT- 2019/06/23 06:00
PHST- 2019/06/23 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
PHST- 2019/06/23 06:00 [entrez]
AID - 10.1007/s11899-019-00519-7 [pii]
AID - 10.1007/s11899-019-00519-7 [doi]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2019 Aug;14(4):228-238. doi: 10.1007/s11899-019-00519-7.